Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription Articles published in Psychiatry Res Retrieve available abstracts of 234 articles: HTML format

Single Articles

October 2025
1. GUO X, Wu S, Jia T, Sun Z, et al
   Plasma fatty acids levels and risk of schizophrenia in the UK Biobank: a prospective cohort study.
   Psychiatry Res. 2025;354:116805.
   PubMed     Abstract available
   
   
   
2. VERDAGUER-RODRIGUEZ M, Lopez-Carrilero R, Diaz-Cutraro L, Ferrer-Quintero M, et al
   Sex-based differences in neurocognitive functioning in first-episode psychosis: An exploratory analysis.
   Psychiatry Res. 2025;354:116803.
   PubMed     Abstract available
   
   
   
3. DELISI LE
   Reflections from half a century of progress searching for the causes of schizophrenia: Stanley Dean award presentation 2025.
   Psychiatry Res. 2025;354:116790.
   PubMed     Abstract available
   
   
   
4. HU G, Wei D, Zhang J, Liu J, et al
   Effect of computerized cognitive remediation therapy combined with individualized occupational therapy on cognitive function and functional outcomes in patients with schizophrenia: A randomized controlled trial.
   Psychiatry Res. 2025;354:116789.
   PubMed     Abstract available
   
   
   
5. ZENCIR T, Celik Zencir A, Tekinarslan G, Koc M, et al
   The role of socioeconomic and structural vulnerability risk factors in employment outcomes for individuals with Schizophrenia and other psychotic disorders.
   Psychiatry Res. 2025;354:116782.
   PubMed     Abstract available
   
   
   
6. MUELLER N, Mulfarth R, Seuffert S, Dannlowski U, et al
   Figurative language production in schizophrenia, bipolar disorder, and depression.
   Psychiatry Res. 2025;354:116772.
   PubMed     Abstract available
   
   
   
7. ASENJO-LOBOS C, Arancibia M, Garcia-Ribera C, Cortes-Jofre M, et al
   Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review.
   Psychiatry Res. 2025;353:116764.
   PubMed     Abstract available
   
   
   
8. PREOBRAZENSKI N, Hsieh T, Robertson C, Thai H, et al
   Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada.
   Psychiatry Res. 2025;352:116684.
   PubMed     Abstract available
   
   
   
9. XUE J, Zhai Z, Li X, Zhu Y, et al
   Deep transcranial magnetic stimulation over the anterior cingulate cortex in treatment-resistant schizophrenia: A pilot double-blind, randomized controlled trial.
   Psychiatry Res. 2025;353:116756.
   PubMed     Abstract available
   
   
   September 2025
10. PANGANIBAN KJ, Smith ECC, Stogios N, Agarwal SM, et al
    The cognitive metabolomic signatures in schizophrenia spectrum disorders: A systematic review.
    Psychiatry Res. 2025;353:116742.
    PubMed     Abstract available
    
    
    
11. MONTI P, Iodice S, Capuzzi E, Borroni E, et al
    Short-term exposure to particulate matter and apparent temperature is associated with schizophrenia severity in Italy.
    Psychiatry Res. 2025;353:116735.
    PubMed     Abstract available
    
    
    
12. SOTERO-MORENO A, Guardiola-Ripoll M, Hostalet N, Moreira M, et al
    Effects of DISC1 and hypoxia-sensitive genes on dermatoglyphics and cognitive function in schizophrenia.
    Psychiatry Res. 2025;353:116721.
    PubMed     Abstract available
    
    
    
13. BIAGETTI R, Caiazza L, Giuva T, Pirani G, et al
    Clozapine-induced cardiac toxicity and successful rechallenge in children and adolescents: a systematic review and new case report.
    Psychiatry Res. 2025;351:116646.
    PubMed     Abstract available
    
    
    
14. GOMBAS SA, Moran EK, Barch DM
    Relationships between cognition and symptoms across mood and psychotic disorders.
    Psychiatry Res. 2025;351:116628.
    PubMed     Abstract available
    
    
    
15. ZHU T, Jiao X, Zhou J, Nicholas PJ, et al
    Efficacy of rTMS on SCZ symptoms: Insights from connectome mapping.
    Psychiatry Res. 2025;351:116568.
    PubMed     Abstract available
    
    
    
16. LU N, Wang M, Zheng Z, Zhang F, et al
    Comorbidity of common psychiatric disorders and attention-deficit/hyperactivity disorder in Chinese adults.
    Psychiatry Res. 2025;351:116662.
    PubMed     Abstract available
    
    
    August 2025
17. PATEL SES, Haut KM, Lee H, Fisher M, et al
    Social cognition training improves recognition of individual emotions in schizophrenia disorder.
    Psychiatry Res. 2025;352:116711.
    PubMed     Abstract available
    
    
    
18. BLAIN SD, Kent JS, Peyromaure de Bord CA, Sponheim SR, et al
    Social cognitive deficits in schizophrenia, bipolar disorder, and first-degree relatives: A large-sample, multi-task investigation.
    Psychiatry Res. 2025;352:116694.
    PubMed     Abstract available
    
    
    
19. JUST SA, Elvevag B, Pandey S, Nenchev I, et al
    Moving beyond word error rate to evaluate automatic speech recognition in clinical samples: Lessons from research into schizophrenia-spectrum disorders.
    Psychiatry Res. 2025;352:116690.
    PubMed     Abstract available
    
    
    
20. WANG Z, Li J, Wang L, Wei Q, et al
    Comparative Effects of Exercise Modalities on Negative Symptoms in Schizophrenia: A Systematic Review and Network Meta-analysis of 32 RCTs.
    Psychiatry Res. 2025;352:116665.
    PubMed     Abstract available
    
    
    
21. ASENJO-LOBOS C, Arancibia M, Cortes-Jofre M, Huang T, et al
    Comparative efficacy and safety of clozapine vs. risperidone in schizophrenia and related disorders: An updated systematic review.
    Psychiatry Res. 2025;351:116670.
    PubMed     Abstract available
    
    
    July 2025
22. DUDLEY R, White S, Miskin R, Oakes L, et al
    Corrigendum to Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis, Psychiatry Research, Vol 342, December 2024, 116229.
    Psychiatry Res. 2025;351:116642.
    PubMed    
    
    
    
23. ARSLAN B, Kizilay E, Turan YE, Verim B, et al
    Computational linguistic investigation in schizophrenia and autism spectrum disorders.
    Psychiatry Res. 2025;351:116633.
    PubMed     Abstract available
    
    
    
24. LEATHEM LD, Barch DM, Moran EK, Patel PK, et al
    Cognitive effort-based decision making in schizophrenia and bipolar disorder: Associations with clinical symptoms and cognitive performance.
    Psychiatry Res. 2025;351:116629.
    PubMed     Abstract available
    
    
    
25. CHIU EC, Lee SC
    Effect of community-based reablement program on quality of life for people with schizophrenia: A randomized controlled study.
    Psychiatry Res. 2025;351:116624.
    PubMed     Abstract available
    
    
    June 2025
26. STUDART I, Rasmussen AR
    OCD with psychotic features or schizophrenia with obsessions and compulsions?
    Psychiatry Res. 2025;351:116619.
    PubMed    
    
    
    
27. SUN X, Qiu Y, Ji L, Li M, et al
    Proteomic characterization of plasma exosomes in drug-naive schizophrenia: Insights into psychosis and cognitive dysfunction.
    Psychiatry Res. 2025;351:116611.
    PubMed     Abstract available
    
    
    
28. SU Q, Wang J, Ge H, Li M, et al
    The relationship between inflammation and cognitive function in drug-naive schizophrenia with or without pre-metabolic syndrome.
    Psychiatry Res. 2025;351:116604.
    PubMed     Abstract available
    
    
    
29. KOTWANI A, Wojtalik JA, Gunzler DD, Smith MJ, et al
    Social cognition as a mediator between neurocognition and functional outcome in early course schizophrenia.
    Psychiatry Res. 2025;351:116594.
    PubMed     Abstract available
    
    
    
30. JACOBSEN SL, Kohler-Forsberg O, Danielsen AA, Rohde C, et al
    Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study.
    Psychiatry Res. 2025;351:116592.
    PubMed     Abstract available
    
    
    
31. AL-KURAISHY HM, Mohammed HA, Sulaiman GM, Jabir MS, et al
    Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review.
    Psychiatry Res. 2025;351:116575.
    PubMed     Abstract available
    
    
    May 2025
32. PILON F, Boisvert M, Mottron L, Potvin S, et al
    A fMRI meta-analysis of emotion processing in the psychosis spectrum reveals no significant alterations in at-risk individuals.
    Psychiatry Res. 2025;351:116565.
    PubMed     Abstract available
    
    
    
33. DODGSON G, Singh A, Barclay N, Birkett L, et al
    Managing unusual sensory experiences in at-risk mental state for psychosis in England: A parallel group, single-blind, randomised controlled feasibility trial.
    Psychiatry Res. 2025;351:116564.
    PubMed     Abstract available
    
    
    
34. SAITOH K, Lajnef M, Boukouaci W, Andre M, et al
    Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohort.
    Psychiatry Res. 2025;350:116557.
    PubMed     Abstract available
    
    
    
35. CHEN B, Tan XW, Tor PC
    Effects of dose on early treatment response to bifrontal electroconvulsive therapy in Schizophrenia: A retrospective study.
    Psychiatry Res. 2025;350:116554.
    PubMed     Abstract available
    
    
    
36. CORONADO-MONTOYA S, Abdel-Baki A, Bodson-Clermont P, Boucher-Roy D, et al
    A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabis.
    Psychiatry Res. 2025;350:116553.
    PubMed     Abstract available
    
    
    
37. TOTZEK JF, Shah JL, Young AL, Malla A, et al
    From resting-state functional hippocampal centrality to functional outcome: An extended neurocognitive model of psychosis.
    Psychiatry Res. 2025;350:116538.
    PubMed     Abstract available
    
    
    
38. GUTIERREZ G, Garcia de Jalon E, Aranguren L, Corrales A, et al
    Corrigendum to 'Antipsychotic discontinuation in nonaffective first-episode psychosis after clinical remission: Insights from the PEPsNa naturalistic study' [ Psychiatry Research volume 342 (December 2024) 1-10/116261].
    Psychiatry Res. 2025 May 16:116539. doi: 10.1016/j.psychres.2025.116539.
    PubMed    
    
    
    
39. LUO H, Li YL, Luo XJ, Xia L, et al
    The efficacy of psychoeducation-based programs on internalized stigma in patients with schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2025;350:116540.
    PubMed     Abstract available
    
    
    
40. HOFMANN AB, Dorner M, Klassen PE, Machetanz L, et al
    RIPTOSO: The development of a screening tool for adverse events during forensic-psychiatric inpatient treatments of offenders with schizophrenia spectrum disorders.
    Psychiatry Res. 2025;350:116537.
    PubMed     Abstract available
    
    
    
41. BERE M, Rossell SL, Toh WL
    Corrigendum to Cognition in relation to non-auditory or multisensory hallucinations in schizophrenia-spectrum disorders: A scoping review.
    Psychiatry Res. 2025;349:116526.
    PubMed    
    
    
    
42. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
    Corrigendum to 'A clinical staging model of psychotic disorders based on a long-term follow-up of first-admission psychosis: A validation study' Psychiatry Res. 2023; 322:115109.
    Psychiatry Res. 2025;349:116530.
    PubMed    
    
    
    April 2025
43. DEMIRLI E, Ahmed AO, Serper M
    Personal recovery and future self-continuity in individuals with schizophrenia.
    Psychiatry Res. 2025;348:116510.
    PubMed     Abstract available
    
    
    
44. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
    Compulsory admission as access to early intervention service for patients with first episode psychosis: What relevance for clinical outcomes? Further findings from the Pr-EP program.
    Psychiatry Res. 2025;349:116507.
    PubMed     Abstract available
    
    
    
45. SALGADO-PINEDA P, Barbosa L, Hostalet N, Garcia-Leon MA, et al
    An ontogenetic role for Broca's and related speech areas in schizophrenic auditory hallucinations? Evidence from sulcal pits analysis.
    Psychiatry Res. 2025;348:116502.
    PubMed     Abstract available
    
    
    
46. CAO C, Liu W, Hou C, Chen Y, et al
    Disrupted default mode network connectivity and its role in negative symptoms of schizophrenia.
    Psychiatry Res. 2025;348:116489.
    PubMed     Abstract available
    
    
    
47. LU J, Gou N, Zhang S, Zhou J, et al
    Dysfunctional striatal-temporal connectivity is associated with a higher risk for violence in patients with schizophrenia.
    Psychiatry Res. 2025;348:116488.
    PubMed     Abstract available
    
    
    March 2025
48. SIMGE UO, Burcu V, Aybuke K, Ezgi C, et al
    Clinical high risk for psychosis in bipolar disorder: Clinical features, cognition and functioning.
    Psychiatry Res. 2025;348:116478.
    PubMed     Abstract available
    
    
    
49. SHAKER NM, Aly El-Gabry D, Abdel Aziz K, Hashem R, et al
    Clinical and neuroradiological differences in obsessive compulsive disorder with and without psychosis.
    Psychiatry Res. 2025;348:116472.
    PubMed     Abstract available
    
    
    
50. KANE JM, Rubio JM, Casciano J, Dotiwala Z, et al
    Real-world outcomes and practice patterns among patients with schizophrenia when switched from oral antipsychotics to long-acting injectable formulations after hospitalization.
    Psychiatry Res. 2025;348:116455.
    PubMed     Abstract available
    
    
    
51. APRILE SF, Rodolico A, Di Francesco A, Varrasi S, et al
    Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: A systematic review of patients' subjective experiences.
    Psychiatry Res. 2025;348:116460.
    PubMed     Abstract available
    
    
    
52. LINDSTROM S, Nordgaard J, Berge J
    Transition from schizotypal disorder to non-affective psychotic disorders including schizophrenia: A nationwide Swedish cohort study.
    Psychiatry Res. 2025;348:116470.
    PubMed     Abstract available
    
    
    
53. BAILEY A, Bauer BW, Mittal VA, Ellman LM, et al
    Interpersonal difficulties and suicidal ideation in young people at clinical high-risk for psychosis and help-seeking clinical controls.
    Psychiatry Res. 2025;348:116467.
    PubMed     Abstract available
    
    
    
54. NEERGAARD KD, Zemla JC, Victor Ortiz-Garcia de la F, Lubrini G, et al
    Novel computational measure of semantic fluency performance associated with first-episode of psychosis.
    Psychiatry Res. 2025;348:116462.
    PubMed     Abstract available
    
    
    
55. SUDAR FP, Zekerallah SS, Paulzen M, Mathiak K, et al
    Unraveling antipsychotic induced weight gain in schizophrenia - A proof-of-concept study exploring the impact of the cumulative historical occupancy of different receptors by antipsychotics.
    Psychiatry Res. 2025;348:116452.
    PubMed     Abstract available
    
    
    
56. SHIMADA T, Ito S, Yamanushi A, Koizumi A, et al
    Effect of aerobic exercise versus cognitive remediation versus a combination of both on cognition among patients with schizophrenia: A three-arm, randomized controlled study.
    Psychiatry Res. 2025;348:116454.
    PubMed     Abstract available
    
    
    
57. GOLDSTEIN KE, Pietrzak RH, Aladin S, Ng S, et al
    Neuro- and social-cognition in schizotypal personality disorder and schizophrenia: A spectrum of severity.
    Psychiatry Res. 2025;348:116445.
    PubMed     Abstract available
    
    
    
58. MEWENGKANG A, Pandolos T, Sengkey MM, Sengkey SB, et al
    Sleep quality vs. mental health: A complex relationship with psychosis.
    Psychiatry Res. 2025;348:116441.
    PubMed    
    
    
    
59. SENTHIL KUMAR L, Chen B, Tan X, Tor PC, et al
    Response to electroconvulsive therapy is not consistently replicated across multiple treatment courses.
    Psychiatry Res. 2025;345:116374.
    PubMed     Abstract available
    
    
    
60. LOHMAN MC, Scott V, Verma M, Jones P, et al
    Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.
    Psychiatry Res. 2025;345:116378.
    PubMed     Abstract available
    
    
    February 2025
61. SOLBERG A, Ottesen A, Barrett EA, Kristiansen I, et al
    Trajectories of suicidal behavior and their clinical correlates in the early phases of schizophrenia spectrum disorders.
    Psychiatry Res. 2025;347:116409.
    PubMed     Abstract available
    
    
    
62. DAMIANI S, D'Imperio A, Radua J, Fortea L, et al
    A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.
    Psychiatry Res. 2025;347:116406.
    PubMed     Abstract available
    
    
    
63. CAI C, Zhao P, Patel C, Benson C, et al
    Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder.
    Psychiatry Res. 2025;346:116402.
    PubMed     Abstract available
    
    
    
64. HANDEST R, Molstrom IM, Henriksen MG, Nordgaard J, et al
    Revisiting the relationship between impaired social functioning and psychopathology in schizophrenia.
    Psychiatry Res. 2025;346:116389.
    PubMed     Abstract available
    
    
    January 2025
65. HUIZER K, Soni S, Schmidt MA, Cakici N, et al
    Potential benefits of ketone therapy as a novel immunometabolic treatment for schizophrenia.
    Psychiatry Res. 2025;345:116379.
    PubMed     Abstract available
    
    
    
66. HWANG H, Kim SM, Kim HJ, Han DH, et al
    Comparison of attention and brain functional connectivity between patient groups with schizophrenia and attention deficit hyperactivity disorder.
    Psychiatry Res. 2025;345:116376.
    PubMed     Abstract available
    
    
    
67. BERISHA F, Paquin V, Gold I, Misic B, et al
    Exploring delusional themes and other symptoms in first episode psychosis: A network analysis over two timepoints.
    Psychiatry Res. 2025;344:116349.
    PubMed     Abstract available
    
    
    
68. GRENDAS LN, Olaviaga A, Chiapella LC, Daray FM, et al
    Incidence rate of suicidal behavior stratified by diagnosis among high-risk patients.
    Psychiatry Res. 2025;343:116310.
    PubMed     Abstract available
    
    
    December 2024
69. LI J, He J, Ren H, Li Z, et al
    Multilayer network instability underlying persistent auditory verbal hallucinations in schizophrenia.
    Psychiatry Res. 2024;344:116351.
    PubMed     Abstract available
    
    
    
70. ZHANG H, He R, Palominos C, Hsu N, et al
    The structure of meaning in schizophrenia: A study of spontaneous speech in Chinese.
    Psychiatry Res. 2024;344:116347.
    PubMed     Abstract available
    
    
    
71. HSIAO CY, Wu KY, Chiu CK, Lu HL, et al
    Development and validation of a schizophrenia literacy scale for individuals diagnosed with schizophrenia.
    Psychiatry Res. 2024;344:116344.
    PubMed     Abstract available
    
    
    
72. PIETERS LE, Deenik J, Hoogendoorn AW, van Someren EJW, et al
    Sleep and physical activity patterns in relation to daily-life symptoms in psychosis: An actigraphy and experience sampling study.
    Psychiatry Res. 2024;344:116320.
    PubMed     Abstract available
    
    
    
73. GARCIA-FERNANDEZ L, Romero-Ferreiro V, Padilla S, Wynn R, et al
    Transcranial direct current stimulation (tDCS) enhances cognitive function in schizophrenia: A randomized double-blind sham-controlled trial.
    Psychiatry Res. 2024;344:116308.
    PubMed     Abstract available
    
    
    
74. WYSOKINSKI A, Dreczka J
    Clozapine Toxicity Predictor: Deep neural network model predicting clozapine toxicity and its therapeutic dose range.
    Psychiatry Res. 2024;342:116256.
    PubMed     Abstract available
    
    
    
75. SOLDEVILA-MATIAS P, Sanchez-Orti JV, Correa-Ghisays P, Balanza-Martinez V, et al
    Exercise as a promoter of neurocognitive improvement in people with psychiatric disorders and comorbid obesity: A randomized controlled trial.
    Psychiatry Res. 2024;342:116226.
    PubMed     Abstract available
    
    
    
76. FLORENTIN S, Neumark Y, Roe D, Rosca P, et al
    The relationship between community-based psychiatric rehabilitation pathways and re-hospitalization trajectories: A three-decade follow-up.
    Psychiatry Res. 2024;342:116216.
    PubMed     Abstract available
    
    
    
77. PISANU C, Congiu D, Meloni A, Paribello P, et al
    Sex differences in shared genetic determinants between severe mental disorders and metabolic traits.
    Psychiatry Res. 2024;342:116195.
    PubMed     Abstract available
    
    
    November 2024
78. SOURANDER A, Silwal S, Surcel HM, Hinkka-Yli-Salomaki S, et al
    Maternal vitamin B12 during pregnancy and schizophrenia in offspring.
    Psychiatry Res. 2024;344:116284.
    PubMed     Abstract available
    
    
    
79. MORITZ S, Leucht S, Hoyer L, Schmotz S, et al
    Towards the DSM-6: The intersection of OCD and psychosis. Expert perspectives on insight in the diagnosis of OCD.
    Psychiatry Res. 2024;344:116306.
    PubMed     Abstract available
    
    
    
80. KHOODORUTH MAS, Hussain T, Ouanes S, Chut-Kai Khoodoruth NW, et al
    Peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia: Insights from a Qatari Cohort.
    Psychiatry Res. 2024;344:116307.
    PubMed     Abstract available
    
    
    
81. KUMAR M, Choudhary H, Chawla N
    Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study: Letter to the editor.
    Psychiatry Res. 2024;343:116299.
    PubMed    
    
    
    
82. GONCALVES CC, Waters Z, Quirk SE, Haddad PM, et al
    Barriers and facilitators to mental health care access and engagement for LGBTQA+ people with psychosis: A scoping review.
    Psychiatry Res. 2024;343:116281.
    PubMed     Abstract available
    
    
    
83. REANGSING C, Wongsuraprakit S, Punsuwun S, Oerther S, et al
    Effects of mindfulness-based interventions (MBIs) on psychotic symptoms and psychological outcomes in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.
    Psychiatry Res. 2024;342:116272.
    PubMed     Abstract available
    
    
    
84. LAMARCA M, Espinosa V, Acuna V, Vila-Badia R, et al
    Reducing self-stigma in psychosis: A systematic review and meta-analysis of psychological interventions.
    Psychiatry Res. 2024;342:116262.
    PubMed     Abstract available
    
    
    
85. BERE M, Rossell SL, Toh WL
    Cognition in relation to non-auditory or multisensory hallucinations in schizophrenia-spectrum disorders: A scoping review.
    Psychiatry Res. 2024;342:116268.
    PubMed     Abstract available
    
    
    
86. ABRAHAM T, Gill H, Wood L
    Psychosocial interventions offered across inpatient and crisis settings to the social networks of service users with psychosis: A systematic review.
    Psychiatry Res. 2024;343:116267.
    PubMed     Abstract available
    
    
    
87. GUTIERREZ G, Garcia de Jalon E, Aranguren L, Corrales A, et al
    Antipsychotic discontinuation in nonaffective first-episode psychosis after clinical remission: Insights from the PEPsNa naturalistic study.
    Psychiatry Res. 2024;342:116261.
    PubMed     Abstract available
    
    
    
88. PUGH SL, Chandler C, Cohen AS, Diaz-Asper C, et al
    Assessing dimensions of thought disorder with large language models: The tradeoff of accuracy and consistency.
    Psychiatry Res. 2024;341:116119.
    PubMed     Abstract available
    
    
    October 2024
89. CALZAVARA PINTON I, Nibbio G, Bertoni L, Cicale A, et al
    The economic burden of schizophrenia spectrum disorders: clinical and functional correlates and predictors of direct costs. A retrospective longitudinal study.
    Psychiatry Res. 2024;342:116240.
    PubMed     Abstract available
    
    
    
90. DEMIRLEK C, Verim B, Zorlu N, Demir M, et al
    Functional brain networks in clinical high-risk for bipolar disorder and psychosis.
    Psychiatry Res. 2024;342:116251.
    PubMed     Abstract available
    
    
    
91. KISIANG'ANI IB, Aden M, Mwangi HR, Akena D, et al
    Exploring psychotic symptoms among substance-naive individuals and recent abstainers without a psychosis diagnosis: A cross-country study across Kenya, Uganda, Ethiopia, and South Africa.
    Psychiatry Res. 2024;342:116253.
    PubMed     Abstract available
    
    
    
92. THIBAUDEAU E, Bowie CR, Montreuil T, Baer L, et al
    Acceptability, engagement, and efficacy of cognitive remediation for cognitive outcomes in young adults with first-episode psychosis and social anxiety: A randomized-controlled trial.
    Psychiatry Res. 2024;342:116243.
    PubMed     Abstract available
    
    
    
93. GONZALES L, Saperstein AM, Qian M, Gorecki A, et al
    Psychiatric and functional correlates of stigma associated with cognitive impairment in schizophrenia.
    Psychiatry Res. 2024;342:116233.
    PubMed     Abstract available
    
    
    
94. CIOFFI L, Wein PY, Miller SA, Fagan S, et al
    Clinical, neurocognitive, neurobiological and functional correlates of sleep difficulties in individuals at-risk for psychosis and mania: A scoping review.
    Psychiatry Res. 2024;342:116235.
    PubMed     Abstract available
    
    
    
95. DUDLEY R, White S, Miskin R, Oakes L, et al
    Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis.
    Psychiatry Res. 2024;342:116229.
    PubMed     Abstract available
    
    
    
96. TORREY EF, Simmons W, Dailey L
    Schizophrenia, clinical and basic research at NIMH: A 75 Year retrospective.
    Psychiatry Res. 2024;342:116225.
    PubMed     Abstract available
    
    
    
97. SARNYAI Z, Ben-Shachar D
    Schizophrenia, a disease of impaired dynamic metabolic flexibility: A new mechanistic framework.
    Psychiatry Res. 2024;342:116220.
    PubMed     Abstract available
    
    
    
98. BERA S, Yang AB, Chung D, Arnesen R, et al
    Duffy-null associated neutrophil count and antipsychotic use.
    Psychiatry Res. 2024;340:116146.
    PubMed    
    
    
    September 2024
99. ARMARIO A, Nadal R, Fuentes S, Visa J, et al
    Prenatal immune activation in rats and adult exposure to inescapable shocks reveal sex-dependent effects on fear conditioning that might be relevant for schizophrenia.
    Psychiatry Res. 2024;342:116219.
    PubMed     Abstract available
    
    
    
100. GIAMPETRUZZI E, Walker EF, Addington J, Bearden CE, et al
     Impact of adverse childhood experiences on risk for internalizing psychiatric disorders in youth at clinical high-risk for psychosis.
     Psychiatry Res. 2024;342:116214.
     PubMed     Abstract available
     
     
     
101. TEYMOURI K, Ebrahimi M, Chen CC, Sriretnakumar V, et al
     Sex-dependent association study of complement C4 gene with treatment-resistant schizophrenia and hospitalization frequency.
     Psychiatry Res. 2024;342:116202.
     PubMed     Abstract available
     
     
     
102. SUKNO FM, Kelly BD, Lane A, Katina S, et al
     Loss of normal facial asymmetry in schizophrenia and bipolar disorder: Implications for development of brain asymmetry in psychotic illness.
     Psychiatry Res. 2024;342:116213.
     PubMed     Abstract available
     
     
     
103. CIUFALO J, Zaccone S, Fatiga G, Caputo GB, et al
     Creative puppet therapy reduces hallucinations in patients diagnosed with schizophrenia: Preliminary findings.
     Psychiatry Res. 2024;342:116211.
     PubMed     Abstract available
     
     
     
104. GLINERT A, Zlidennyy V, Turjeman S, Sharon E, et al
     What's GABA got to do with it? A potential link between the microbiome, schizophrenia, and the endo-cannabinoid system.
     Psychiatry Res. 2024;342:116196.
     PubMed     Abstract available
     
     
     
105. DOMINGUEZ T, Puebla DP, Fresan A, Sheinbaum T, et al
     Why do some Mexicans with psychosis risk symptoms seek mental health care and others do not?
     Psychiatry Res. 2024;342:116199.
     PubMed     Abstract available
     
     
     
106. CASANOVAS F, Dinamarca F, Posso M, Mane A, et al
     Cancer characteristics in patients with schizophrenia: a 25-year retrospective analysis.
     Psychiatry Res. 2024;342:116206.
     PubMed     Abstract available
     
     
     
107. MEHTA UM, Roy N, Bahuguna A, Kotambail A, et al
     Incremental predictive value of genetic risk and functional brain connectivity in determining antipsychotic response in schizophrenia.
     Psychiatry Res. 2024;342:116201.
     PubMed     Abstract available
     
     
     
108. TANG JMY, Chiu KKY, Yang C, Cheung DSK, et al
     Social cognition interventions for patients with first-episode psychosis: A scoping review.
     Psychiatry Res. 2024;342:116191.
     PubMed     Abstract available
     
     
     
109. KRISTENSEN TD, Mager FM, Ambrosen KS, Barber AD, et al
     Cognitive profiles across the psychosis continuum.
     Psychiatry Res. 2024;342:116168.
     PubMed     Abstract available
     
     
     
110. D'ANDREA G, Ouellet-Plamondon C, Villeneuve M, Shah JL, et al
     Joint-trajectories of clinical severity, social functioning and cannabis use in first-episode psychosis: A 5-year longitudinal study in 2 urban early intervention services.
     Psychiatry Res. 2024;342:116184.
     PubMed     Abstract available
     
     
     
111. VALT C, Lopez-Caballero F, Tavella A, Altamura M, et al
     Abnormal inter-hemispheric effective connectivity from left to right auditory regions during Mismatch Negativity (MMN) tasks in psychosis.
     Psychiatry Res. 2024;342:116189.
     PubMed     Abstract available
     
     
     
112. BORNHEIMER LA, Bagge CL, Overholser J, Brdar NM, et al
     Demographic and clinical characteristics of individuals with psychosis symptoms who died by suicide: Findings of a psychological autopsy study.
     Psychiatry Res. 2024;342:116185.
     PubMed     Abstract available
     
     
     
113. HSIEH KP, Liao WL, Ho PS, Lin JW, et al
     Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study.
     Psychiatry Res. 2024;342:116171.
     PubMed     Abstract available
     
     
     
114. DE HAAS HJ, Cohen D, de Koning MB, van Weringh G, et al
     Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER).
     Psychiatry Res. 2024;339:116070.
     PubMed     Abstract available
     
     
     
115. PICCHIONI M, Ruiz R, de Girolamo G, Iozzino L, et al
     The predictive validity and temporal characteristics of the HCR-20v3 for inpatient violence in forensic inpatient settings. An international study.
     Psychiatry Res. 2024;339:116079.
     PubMed     Abstract available
     
     
     
116. ZACHOS KA, Choi J, Godin O, Chernega T, et al
     Mitochondrial Biomarkers and Metabolic Syndrome in Bipolar Disorder.
     Psychiatry Res. 2024;339:116063.
     PubMed     Abstract available
     
     
     
117. LUYKX JJ, Tanskanen A, Lahteenvuo M, Manu P, et al
     Dopamine D2 receptor antagonism of antipsychotics and the risk of death due to choking.
     Psychiatry Res. 2024;339:116012.
     PubMed     Abstract available
     
     
     August 2024
118. MORKVED N, Johnsen E, Kroken RA, Joa I, et al
     Childhood trauma types in relation to antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, randomized controlled study.
     Psychiatry Res. 2024;341:116169.
     PubMed     Abstract available
     
     
     
119. SNELLEKSZ M, Dean B
     Higher levels of AKT-interacting protein in the frontal pole from people with schizophrenia are limited to a sub-group who have a marked deficit in cortical muscarinic M1 receptors.
     Psychiatry Res. 2024;341:116156.
     PubMed     Abstract available
     
     
     
120. MORO L, Sicotte R, Joober R, Malla A, et al
     Trajectories of suicidality during a 2-year early-intervention program for first-episode psychosis: A longitudinal study.
     Psychiatry Res. 2024;340:116148.
     PubMed     Abstract available
     
     
     
121. COHEN S, Goldsmith DR, Ning CS, Addington J, et al
     Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis.
     Psychiatry Res. 2024;341:116147.
     PubMed     Abstract available
     
     
     
122. TSUI HKH, Luk SL, Hsiao J, Chan SKW, et al
     Facial emotion perception in individuals with clinical high risk for psychosis compared with healthy controls, first-episode psychosis, and in predicting psychosis transition: A systematic review and meta-analysis.
     Psychiatry Res. 2024;340:116143.
     PubMed     Abstract available
     
     
     
123. GUZMAN A, Klein H, Keefe RS, Horan WP, et al
     Location-based differences in cognition and functional capacity: Consistent levels of impairment in participants with schizophrenia compared to healthy controls.
     Psychiatry Res. 2024;340:116121.
     PubMed     Abstract available
     
     
     
124. GIANNOUCHOS TV, Ohsfeldt RL, Kum HC
     Trends and disparities in emergency department visits for schizophrenia spectrum disorders in Texas from 2019 to 2022.
     Psychiatry Res. 2024;340:116139.
     PubMed    
     
     
     
125. MENDEZ-VICTORIANO G, Zhu Y, Middleton F, Massa PT, et al
     Increased Parenchymal Macrophages are associated with decreased Tyrosine Hydroxylase mRNA levels in the Substantia Nigra of people with Schizophrenia and Bipolar Disorder.
     Psychiatry Res. 2024;340:116141.
     PubMed     Abstract available
     
     
     
126. VITA G, Pollini D, Canozzi A, Papola D, et al
     Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis.
     Psychiatry Res. 2024;340:116124.
     PubMed     Abstract available
     
     
     
127. VITA A, Nibbio G, Barlati S
     Conceptualization and characterization of "primary" and "secondary" cognitive impairment in schizophrenia.
     Psychiatry Res. 2024;340:116126.
     PubMed     Abstract available
     
     
     July 2024
128. MAZZAROTTO F, Monteleone P, Minelli A, Mattevi S, et al
     Genetic determinants of coping, resilience and self-esteem in schizophrenia suggest a primary role for social factors and hippocampal neurogenesis.
     Psychiatry Res. 2024;340:116107.
     PubMed     Abstract available
     
     
     
129. GREVE AN, Hemager N, Mortensen EL, Gantriis DL, et al
     Comparing cognition in parents with schizophrenia or bipolar disorder and their 7-year-old offspring.
     Psychiatry Res. 2024;340:116112.
     PubMed     Abstract available
     
     
     
130. LUCARINI V, Grice M, Wehrle S, Cangemi F, et al
     Language in interaction: turn-taking patterns in conversations involving individuals with schizophrenia.
     Psychiatry Res. 2024;339:116102.
     PubMed     Abstract available
     
     
     
131. BLOSE BA, Silverstein SM, Stuart KV, Keane PA, et al
     Association between polygenic risk for schizophrenia and retinal morphology: A cross-sectional analysis of the United Kingdom Biobank.
     Psychiatry Res. 2024;339:116106.
     PubMed     Abstract available
     
     
     
132. FEKIH-ROMDHANE F, Ghrissi F, Abassi B, Loch AA, et al
     Impulsivity as a predictor of clinical and psychological outcomes in a naturalistic prospective cohort of subjects at ultra-high risk (UHR) for psychosis from Tunisia.
     Psychiatry Res. 2024;340:116090.
     PubMed     Abstract available
     
     
     
133. COFFMAN BA, Curtis M, Seebold D, Kocsis J, et al
     Long-latency auditory evoked response amplitudes at first episode of psychosis predict six-month recovery in positive symptom severity.
     Psychiatry Res. 2024;339:116094.
     PubMed     Abstract available
     
     
     
134. LOURENCO PJDS, Bastos TCL, Pizarro AIN, Corredeira RMN, et al
     Feasibility and effectiveness of a 24-weeks outdoor exercise program on the physical and mental health of persons with schizophrenia.
     Psychiatry Res. 2024;339:116093.
     PubMed     Abstract available
     
     
     
135. THELWELL ELR, Dunkerley L, Goodwin R, Giacco D, et al
     Effectiveness of online social networking interventions on social isolation and quality of life of people with psychosis: A systematic review.
     Psychiatry Res. 2024;339:116088.
     PubMed     Abstract available
     
     
     
136. BIAN Y, Kawabata R, Enwright JF, Tsubomoto M, et al
     Expression of activity-regulated transcripts in pyramidal neurons across the cortical visuospatial working memory network in unaffected comparison individuals and individuals with schizophrenia.
     Psychiatry Res. 2024;339:116084.
     PubMed     Abstract available
     
     
     
137. SCHUTZ A, Salahuddin NH, Priller J, Bighelli I, et al
     The role of control groups in non-pharmacological randomised controlled trials of treatment-resistant schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2024;339:116069.
     PubMed     Abstract available
     
     
     
138. SIDDI S, Ochoa S, Laroi F, Lincoln TM, et al
     A cross-national investigation of psychosis-like experiences in five European countries included in the E-CLECTIC study: Psychometric challenges in studying their measurement.
     Psychiatry Res. 2024;339:116072.
     PubMed     Abstract available
     
     
     
139. WANNAN CMJ, Eratne D, Santillo AF, Malpas C, et al
     Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls.
     Psychiatry Res. 2024;339:116073.
     PubMed     Abstract available
     
     
     
140. WILTSCHKO M
     Is grammar affected in Schizophrenia?
     Psychiatry Res. 2024;339:116061.
     PubMed    
     
     
     
141. CHAN SKW, Pang TSW, Tsui HKH, Suen YN, et al
     Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
     Psychiatry Res. 2024;337:115985.
     PubMed     Abstract available
     
     
     June 2024
142. MELISSA B, Sabrina G, Charles-Edouard G, Hind Z, et al
     Clinical characteristics associated with functioning trajectories following admission to a psychiatric institution: A prospective cohort study of individuals with psychosis.
     Psychiatry Res. 2024;339:116062.
     PubMed     Abstract available
     
     
     
143. COLIJN MA
     Genetic testing in individuals experiencing psychosis: A practical guide for psychiatrists.
     Psychiatry Res. 2024;339:116052.
     PubMed    
     
     
     
144. ANDERSEN HG, DellaValle B, Bogehave H, Mogensen PB, et al
     Glycocalyx shedding patterns identifies antipsychotic-naive patients with first-episode psychosis.
     Psychiatry Res. 2024;339:116037.
     PubMed     Abstract available
     
     
     
145. NADER G, Qureshi M, Chaudhary Z, Fischer CE, et al
     Effect of personality traits, psychological resilience and life adversities on lifetime violence trajectories: A novel classification model in schizophrenia.
     Psychiatry Res. 2024;339:116044.
     PubMed     Abstract available
     
     
     
146. CHIEN WT, Chong YY, Bressington D, McMaster CW, et al
     A randomized controlled trial of an acceptance-based, insight-inducing medication adherence therapy (AIM-AT) for adults with early-stage psychosis.
     Psychiatry Res. 2024;339:116046.
     PubMed     Abstract available
     
     
     
147. FERRARA M, Domenicano I, Marchi A, Zaffarami G, et al
     First episode psychoses in people over-35 years old: uncovering potential actionable targets for early intervention services.
     Psychiatry Res. 2024;339:116034.
     PubMed     Abstract available
     
     
     
148. POUSA E, Brebion G, Lopez-Carrilero R, Ruiz AI, et al
     Predictors of clinical insight in first-episode psychosis: Different patterns in men and women.
     Psychiatry Res. 2024;339:116036.
     PubMed     Abstract available
     
     
     
149. HOSTALET N, Gonzalez A, Salgado-Pineda P, Gonzalez-Colom R, et al
     Face-brain correlates as potential sex-specific biomarkers for schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;339:116027.
     PubMed     Abstract available
     
     
     
150. BUCCI S, Berry N, Ainsworth J, Berry K, et al
     Effects of Actissist, a digital health intervention for early psychosis: A randomized clinical trial.
     Psychiatry Res. 2024;339:116025.
     PubMed     Abstract available
     
     
     
151. CHENG KY, Robinson N, Ploner A, Kuja-Halkola R, et al
     Impact of traumatic brain injury on risk for schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;339:115990.
     PubMed     Abstract available
     
     
     
152. ROTELLA F, Falone A, Cassioli E, Mannucci E, et al
     The effect of differences in trial design on estimates of efficacy of olanzapine in randomized studies.
     Psychiatry Res. 2024;336:115895.
     PubMed     Abstract available
     
     
     
153. MISHRA A, Maiti R, Ramasubbu MK, Srinivasan A, et al
     Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data.
     Psychiatry Res. 2024;338:115989.
     PubMed     Abstract available
     
     
     May 2024
154. WASTLER HM, Mengda Y, Pan X, Bornheimer LA, et al
     Trajectories of suicidal risk among individuals with first-episode psychosis: Relationship to recovery and symptoms.
     Psychiatry Res. 2024;338:115978.
     PubMed     Abstract available
     
     
     
155. COLLINS M, Bartholomeusz C, Mei C, Kerr M, et al
     Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis.
     Psychiatry Res. 2024;337:115966.
     PubMed     Abstract available
     
     
     
156. SANGIMINO M, Babbitt K, Lee HS, Park S, et al
     Bodily experiences of trauma and psychosis risk.
     Psychiatry Res. 2024;337:115961.
     PubMed     Abstract available
     
     
     
157. OH H, Karcher NR, Li Verdugo J, Botello R, et al
     Ethno-racial disparities in psychosis-like experiences among students in higher education: Findings from the Healthy Minds Study 2020-2021.
     Psychiatry Res. 2024;337:115959.
     PubMed     Abstract available
     
     
     
158. WU Y, Zhang CY, Zhang Y, Chen R, et al
     Genomic landscape and functional characterization of structural variations in schizophrenia and bipolar disorder.
     Psychiatry Res. 2024;337:115929.
     PubMed     Abstract available
     
     
     
159. BULDUK BK, Tortajada J, Valiente-Palleja A, Callado LF, et al
     High number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controls.
     Psychiatry Res. 2024;337:115928.
     PubMed     Abstract available
     
     
     April 2024
160. GUO H, Zhong S, Lam ST, Wang N, et al
     Trends in violent offending among people with schizophrenia: A 10-year ecological study.
     Psychiatry Res. 2024;337:115935.
     PubMed     Abstract available
     
     
     
161. BRADLEY ER, Portanova J, Woolley JD, Buck B, et al
     Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia.
     Psychiatry Res. 2024;336:115893.
     PubMed     Abstract available
     
     
     
162. SMITH LC, Mateos AC, Due AS, Bergstrom J, et al
     Immersive virtual reality in the treatment of auditory hallucinations: A PRISMA scoping review.
     Psychiatry Res. 2024;334:115834.
     PubMed     Abstract available
     
     
     March 2024
163. SPINAZZOLA E, Quattrone D, Quattrone A, Murray RM, et al
     The increased incidence of psychosis during the COVID-19 pandemic in South London: The role of heavy cannabis use.
     Psychiatry Res. 2024;336:115869.
     PubMed    
     
     
     
164. HAMZEHPOUR L, Bohn T, Dutsch V, Jaspers L, et al
     From brain to body: exploring the connection between altered reward processing and physical fitness in schizophrenia.
     Psychiatry Res. 2024;335:115877.
     PubMed     Abstract available
     
     
     
165. GALLEGO JA, McNamara RK, Blanco EA, Castaneda S, et al
     Evidence for cytokine dysregulation in schizophrenia spectrum disorders: A comparison of cerebrospinal fluid and blood samples.
     Psychiatry Res. 2024;335:115871.
     PubMed     Abstract available
     
     
     
166. SEFIK E, Guest RM, Aberizk K, Espana R, et al
     Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity.
     Psychiatry Res. 2024;335:115867.
     PubMed     Abstract available
     
     
     
167. SETHI S, Wakeham D, Ketter T, Hooshmand F, et al
     Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial.
     Psychiatry Res. 2024;335:115866.
     PubMed     Abstract available
     
     
     
168. YANG H, Zhu D, Liu Y, Xu Z, et al
     Employing graph attention networks to decode psycho-metabolic interactions in Schizophrenia.
     Psychiatry Res. 2024;335:115841.
     PubMed     Abstract available
     
     
     
169. KISHI T, Citrome L, Sakuma K, Iwata N, et al
     A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
     Psychiatry Res. 2024;333:115761.
     PubMed     Abstract available
     
     
     February 2024
170. GORORA ME, Dalkner N, Moore RC, Depp CA, et al
     A meta-cognitive Wisconsin Card Sorting Test in people with schizophrenia and bipolar disorder: Self-assessment of sorting performance.
     Psychiatry Res. 2024;334:115831.
     PubMed     Abstract available
     
     
     
171. QIN K, Yu Y, Cai H, Li J, et al
     Effectiveness of mindfulness-based intervention in schizophrenia: A meta-analysis of randomized controlled trials.
     Psychiatry Res. 2024;334:115808.
     PubMed     Abstract available
     
     
     
172. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
     Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia.
     Psychiatry Res. 2024;334:115810.
     PubMed     Abstract available
     
     
     
173. GOODING DC, Mohrbacher DA, Umucu E, Van Hulle CA, et al
     Ethnoracialized group differences in attitudes and knowledge about schizophrenia and willingness to engage in biomarker research: The UBIGR Study.
     Psychiatry Res. 2024;334:115776.
     PubMed     Abstract available
     
     
     
174. HYATT AS, Mulvaney-Day N, Chow CM, Cook BL, et al
     Association between electronic nicotine product use and subsequent first episode psychosis.
     Psychiatry Res. 2024;334:115785.
     PubMed     Abstract available
     
     
     
175. KWAK PP, Ibarra C, Hernandez A, Carrasco J, et al
     Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.
     Psychiatry Res. 2024;334:115788.
     PubMed     Abstract available
     
     
     
176. QUIRINO AHA, da Rocha MEC, Andrade AGM, E Souza FGM, et al
     The demonstrated association: Cannabis use and onset of psychosis in the study by Medeiros et al., refuting the reverse notion.
     Psychiatry Res. 2024;334:115771.
     PubMed    
     
     
     January 2024
177. HE R, Palominos C, Zhang H, Alonso-Sanchez MF, et al
     Navigating the semantic space: Unraveling the structure of meaning in psychosis using different computational language models.
     Psychiatry Res. 2024;333:115752.
     PubMed     Abstract available
     
     
     
178. KOS C, Bais L, Klaasen N, Opmeer E, et al
     Effects of right prefrontal theta-burst transcranial magnetic stimulation or transcranial direct current stimulation on apathy in patients with schizophrenia: A multicenter RCT.
     Psychiatry Res. 2024;333:115743.
     PubMed     Abstract available
     
     
     
179. YI S, Wang Q, Wang W, Hong C, et al
     Efficacy of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia: An umbrella review of systematic reviews and meta-analyses.
     Psychiatry Res. 2024;333:115728.
     PubMed     Abstract available
     
     
     
180. TOUMAIAN M, Covanis P, Mantas A, Karantinos T, et al
     Multisensory integration deficits in Schizophrenia and Autism evidenced in behaviour but not event related potentials.
     Psychiatry Res. 2024;332:115727.
     PubMed     Abstract available
     
     
     
181. PROHENS L, Rodriguez N, Segura AG, Martinez-Pinteno A, et al
     Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.
     Psychiatry Res. 2024;332:115722.
     PubMed     Abstract available
     
     
     
182. JEROME L, Matanov A, Bird V, Priebe S, et al
     Comparison of subjective quality of life domains in schizophrenia, mood, and anxiety disorders; an individual patient data meta-analysis.
     Psychiatry Res. 2024;332:115707.
     PubMed     Abstract available
     
     
     
183. CHU RST, Chong RCH, Chang DHH, Shan Leung AL, et al
     The risk of stroke and post-stroke mortality in people with schizophrenia: A systematic review and meta-analysis study.
     Psychiatry Res. 2024;332:115713.
     PubMed     Abstract available
     
     
     
184. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Ojeda N, et al
     Premorbid adjustment as predictor of long-term functionality: Findings from a 10-year follow-up study in the PAFIP-cohort.
     Psychiatry Res. 2024;331:115674.
     PubMed     Abstract available
     
     
     
185. MASTELLARI T, Saint-Dizier C, Fovet T, Geoffroy PA, et al
     Exploring seasonality in catatonia diagnosis: Evidence from a large-scale population study.
     Psychiatry Res. 2024;331:115652.
     PubMed     Abstract available
     
     
     December 2023
186. WANG Y, Zhang X
     The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia.
     Psychiatry Res. 2023;332:115708.
     PubMed     Abstract available
     
     
     
187. VGONTZAS AN, Paschalidou A, Simos PG, Anastasaki M, et al
     Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder.
     Psychiatry Res. 2023;332:115676.
     PubMed     Abstract available
     
     
     
188. TORREY EF
     Did the human genome project affect research on Schizophrenia?
     Psychiatry Res. 2023;333:115691.
     PubMed     Abstract available
     
     
     
189. KIM WS, Shen J, Tsogt U, Odkhuu S, et al
     Altered thalamic volumes and functional connectivity in the recovered patients with psychosis.
     Psychiatry Res. 2023;331:115688.
     PubMed     Abstract available
     
     
     
190. ZHOU D, Xie H, Chen L, Zhu Z, et al
     The cognitive improvement in patients with schizophrenia following low-intensity repetitive transcranial magnetic stimulation could last for 6 months: A randomized controlled trial.
     Psychiatry Res. 2023;332:115672.
     PubMed     Abstract available
     
     
     
191. CHEN Y, Zhang L, Sun Y, Wang W, et al
     Prevalence of constipation in patients with schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2023;331:115659.
     PubMed    
     
     
     
192. DE MEDEIROS MW, Andrade JC, Haddad NM, Mendonca M, et al
     Cannabis use influences disorganized symptoms severity but not transition in a cohort of non-help-seeking individuals at-risk for psychosis from Sao Paulo, Brazil.
     Psychiatry Res. 2023;331:115665.
     PubMed     Abstract available
     
     
     
193. DEAN B, Duce J, Li QX, Masters CL, et al
     Lower levels of soluble beta-amyloid precursor protein, but not beta-amyloid, in the frontal cortex in schizophrenia.
     Psychiatry Res. 2023;331:115656.
     PubMed     Abstract available
     
     
     
194. FENG XZ, Li Z, Li ZY, Wang K, et al
     Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.
     Psychiatry Res. 2023;332:115637.
     PubMed     Abstract available
     
     
     
195. VINOGRADOV S
     Harnessing neuroplasticity.
     Psychiatry Res. 2023;330:115607.
     PubMed     Abstract available
     
     
     
196. STAFFORD E, Jakob S, Gur RE, Corcoran CM, et al
     Securing direct stakeholder feedback to inform clinical research in serious mental illness: Results of a patient and family perspectives survey.
     Psychiatry Res. 2023;330:115574.
     PubMed     Abstract available
     
     
     November 2023
197. GROENING JM, Denton E, Parvaiz R, Brunet DL, et al
     A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses.
     Psychiatry Res. 2023;331:115626.
     PubMed     Abstract available
     
     
     
198. LAMANNA-RAMA N, Romero-Miguel D, Casquero-Veiga M, MacDowell KS, et al
     THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation.
     Psychiatry Res. 2023;331:115643.
     PubMed     Abstract available
     
     
     
199. WEI Z, Wang Y, Hu L, Wang Y, et al
     Incidence, prevalence, and mortality of schizophrenia from 2016 to 2020 in Shandong, China.
     Psychiatry Res. 2023;331:115612.
     PubMed     Abstract available
     
     
     
200. LEE J, Xue X, Au E, McIntyre WB, et al
     Central insulin dysregulation in antipsychotic-naive first-episode psychosis: In silico exploration of gene expression signatures.
     Psychiatry Res. 2023;331:115636.
     PubMed     Abstract available
     
     
     
201. CUESTA MJ, Gil-Berrozpe GJ, Sanchez-Torres AM, Moreno-Izco L, et al
     20-Year trajectories of six psychopathological dimensions in patients with first-episode psychosis: Could they be predicted?
     Psychiatry Res. 2023;331:115614.
     PubMed     Abstract available
     
     
     
202. HU Q, Jiao X, Zhou J, Tang Y, et al
     Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial.
     Psychiatry Res. 2023;330:115600.
     PubMed     Abstract available
     
     
     
203. BOGE K, Hallford DJ, Pillny M
     Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls - A multicenter cross-sectional study.
     Psychiatry Res. 2023;330:115591.
     PubMed     Abstract available
     
     
     
204. DAZZAN P
     Disentangling psychosis: The challenges of informing precision medicine for what is not a single disorder.
     Psychiatry Res. 2023;330:115596.
     PubMed     Abstract available
     
     
     
205. BERNARDIN F, Gauld C, Martin VP, Laprevote V, et al
     The 68 symptoms of the clinical high risk for psychosis: Low similarity among fourteen screening questionnaires.
     Psychiatry Res. 2023;330:115592.
     PubMed     Abstract available
     
     
     
206. CORNBLATT BA, McFarlane WR, Carrion RE
     Authors' reply to comments on: Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
     Psychiatry Res. 2023;330:115594.
     PubMed    
     
     
     
207. KIRSHENBAUM AP, Sofis MJ, Slade M
     Response to recreational cannabis use over time in individuals at clinical high risk for psychosis: lack of associations with symptom, neurocognitive, functioning, and treatment patterns by Carrion et al., 2023.
     Psychiatry Res. 2023;330:115589.
     PubMed    
     
     
     
208. PARK S
     Schizophrenia in the mind, the brain and the body.
     Psychiatry Res. 2023;329:115547.
     PubMed     Abstract available
     
     
     October 2023
209. BIRONG CHEN, Tan XW, Tor PC
     The impact of the number of previous illness episodes on early response to electroconvulsive therapy (ECT) in psychosis, mania, depression, psychotic depression, and catatonia: A naturalistic transdiagnostic analysis.
     Psychiatry Res. 2023;330:115580.
     PubMed     Abstract available
     
     
     
210. KIM HK, Goncalves VF, Husain MI, Muller DJ, et al
     Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.
     Psychiatry Res. 2023;330:115563.
     PubMed     Abstract available
     
     
     
211. LIN CH, Huang CJ, Lin TC, Chan HY, et al
     Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
     Psychiatry Res. 2023;330:115575.
     PubMed     Abstract available
     
     
     
212. WANG P, Jiang Y, Hoptman MJ, Li Y, et al
     Structural-functional connectivity deficits of callosal-white matter-cortical circuits in schizophrenia.
     Psychiatry Res. 2023;330:115559.
     PubMed     Abstract available
     
     
     
213. VAN DER TUIN S, Booij SH, Muller MK, van den Berg D, et al
     The added value of daily diary data in 1- and 3-year prediction of psychopathology and psychotic experiences in individuals at risk for psychosis.
     Psychiatry Res. 2023;329:115546.
     PubMed     Abstract available
     
     
     
214. HASSAN L, Eisner E, Berry K, Emsley R, et al
     User engagement in a randomised controlled trial for a digital health intervention for early psychosis (Actissist 2.0 trial).
     Psychiatry Res. 2023;329:115536.
     PubMed     Abstract available
     
     
     
215. SCHLIEF M, Rich N, Rains LS, Baldwin H, et al
     Ethnic differences in receipt of psychological interventions in Early Intervention in Psychosis services in England - a cross-sectional study.
     Psychiatry Res. 2023;330:115529.
     PubMed     Abstract available
     
     
     
216. ZHANG T, Xu L, Wei Y, Tang X, et al
     Duration of untreated prodromal psychosis among individuals with clinical high risk for psychosis.
     Psychiatry Res. 2023;329:115522.
     PubMed     Abstract available
     
     
     September 2023
217. SAMPEDRO A, Pena J, Sanchez P, Ibarretxe-Bilbao N, et al
     Moderators of functional improvement after integrative cognitive remediation in schizophrenia: Toward a personalized treatment approach.
     Psychiatry Res. 2023;329:115495.
     PubMed     Abstract available
     
     
     
218. HUI CLM, Wong CCL, Chan EWT, Suen YN, et al
     COVID-19 exposure and psychosis: A comparison of clinical, functional, and cognitive profiles in remitted patients with psychosis.
     Psychiatry Res. 2023;328:115487.
     PubMed     Abstract available
     
     
     
219. CAMPRODON-BOADAS P, De la Serna E, Plana MT, Flamarique I, et al
     Delusional beliefs in adolescents with anorexia nervosa, obsessive-compulsive disorder, or first-episode psychosis: A comparative study.
     Psychiatry Res. 2023;328:115490.
     PubMed     Abstract available
     
     
     
220. BALDINI V, Stefano RD, Rindi LV, Ahmed AO, et al
     Association between adverse childhood experiences and suicidal behavior in schizophrenia spectrum disorders: A systematic review and meta-analysis.
     Psychiatry Res. 2023;329:115488.
     PubMed     Abstract available
     
     
     
221. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
     Introducing an interview-based cognitive assessment tool for people with Schizophrenia in Ethiopia.
     Psychiatry Res. 2023;328:115474.
     PubMed     Abstract available
     
     
     
222. SANCHEZ-TORRES AM, Garcia de Jalon E, Gil-Berrozpe GJ, Peralta V, et al
     Cognitive intraindividual variability, cognitive impairment and psychosocial functioning in first-episode psychosis patients.
     Psychiatry Res. 2023;328:115473.
     PubMed     Abstract available
     
     
     
223. FORDHAM E, Gao CX, Filia K, O'Donoghue B, et al
     Social disadvantage in early psychosis and its effect on clinical presentation and service access, engagement and use.
     Psychiatry Res. 2023;328:115478.
     PubMed     Abstract available
     
     
     
224. MAURUS I, Roell L, Lembeck M, Papazova I, et al
     Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial.
     Psychiatry Res. 2023;328:115480.
     PubMed     Abstract available
     
     
     
225. INCHAUSTI L, Gorostiza I, Gonzalez Torres MA, Oraa R, et al
     The transition to Schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use.
     Psychiatry Res. 2023;328:115475.
     PubMed     Abstract available
     
     
     
226. FANG X, Gao C, Wu W, Hu X, et al
     The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a cross-sectional study.
     Psychiatry Res. 2023;328:115463.
     PubMed     Abstract available
     
     
     
227. ZHANG J, Yang Y, Liu T, Shi Z, et al
     Functional connectivity in people at clinical and familial high risk for schizophrenia.
     Psychiatry Res. 2023;328:115464.
     PubMed     Abstract available
     
     
     
228. SMITH ECC, Au E, Pereira S, Sharma E, et al
     Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.
     Psychiatry Res. 2023;328:115472.
     PubMed     Abstract available
     
     
     
229. LUCKHOFF HK, Asmal L, Smit R, Phahladira L, et al
     Sex, gender, and outcome in first-episode psychosis: The role of premorbid functioning.
     Psychiatry Res. 2023;328:115460.
     PubMed     Abstract available
     
     
     
230. SEGAL SP, Rimes L, Badran L
     Crime and victimization outcomes following civil rights limits to the use of compulsory treatment.
     Psychiatry Res. 2023;327:115377.
     PubMed     Abstract available
     
     
     
231. JOSHI YB, Gonzalez CE, Molina JL, MacDonald LR, et al
     Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders.
     Psychiatry Res. 2023;327:115215.
     PubMed     Abstract available
     
     
     
232. XIE Y, Guan M, Wang Z, Ma Z, et al
     Alterations in brain connectivity patterns in schizophrenia patients with auditory verbal hallucinations during low frequency repetitive transcranial magnetic stimulation.
     Psychiatry Res. 2023;328:115457.
     PubMed     Abstract available
     
     
     August 2023
233. CARRION RE, Auther AM, McLaughlin D, Adelsheim S, et al
     Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
     Psychiatry Res. 2023;328:115420.
     PubMed     Abstract available
     
     
     
234. JOHANSSON M, Hjarthag F, Helldin L
     Exploring cross-sectional and longitudinal symptomatic remission and subjective quality of life in schizophrenia.
     Psychiatry Res. 2023;328:115421.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.